Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

2023243 citationsJournal Articlegreen Open Access

Authors

Stéphanie Meier · University of Basel

Eline A.J. Willemse · University of Basel

Sabine Schaedelin · University of Basel

Johanna Oechtering · University of Basel

Johannes Lorscheider · University of Basel

Lester Melie‐García · University of Basel

Alessandro Cagol ·

Abstract

Results of this cohort study suggest that sGFAP is a prognostic biomarker for future PIRA and revealed its complementary potential next to sNfL. sGFAP may serve as a useful biomarker for disease progression in MS in individual patient management and drug development.

Topics & Keywords

Multiple Sclerosis Research Studies Amyotrophic Lateral Sclerosis Research Peripheral Neuropathies and Disorders

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: JAMA Neurology

Volume 80, Issue 3, pp. 287-287

DOI: 10.1001/jamaneurol.2022.5250

Field-Weighted Citation Impact: 61.19